Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Challenges of Fundraising a Merger
When you were on the fundraising trial and looking at VCs, it was a challenging environment. It's even more challenging today, I think, than it was a couple of years ago. And we don't know right now, which is absolutely linked to one cytokine by itself, except genetic defects. Yeah. That sort of general, I guess, sentiment that's out there in the industry can certainly be contagious.
Transcript
Play full episode
